机器人辅助根治性膀胱切除术治疗非肌层浸润性膀胱癌的长期多中心分析
多中心前瞻性数据库(2004—2022年)回顾分析355例非肌层浸润性膀胱癌患者行机器人辅助根治性膀胱切除术加体内尿流改道,12年总生存率49%、癌症特异性生存率76%;分期升级与更差生存相关,合并原位癌、变异组织学等为分期升级预测因素。
要点
- 355例非肌层浸润性膀胱癌行机器人辅助根治性膀胱切除术加体内尿流改道,12年总生存率49%、癌症特异性生存率76%。
- 分期升级者12年总生存率39% vs 未升级者52%,癌症特异性生存率68% vs 79%,差异有统计学意义(P < 0.001)。
- 年龄≥83岁(OR 19.7)、合并原位癌(OR 2.7)、鳞状细胞癌(OR 6.6)、变异组织学(OR 6.2)预测分期升级。
核心结论
- 本研究提供了机器人辅助根治性膀胱切除术治疗非肌层浸润性膀胱癌的最长随访数据。
- 合并原位癌、变异组织学和经尿道膀胱肿瘤电切术时为pT1是分期升级的预测因素,分期升级与更高复发和更差生存相关。
- 机器人辅助根治性膀胱切除术加体内尿流改道是需要早期膀胱切除术的非肌层浸润性膀胱癌患者的一种微创选择,提供可比的长期结局。
研究设计与样本
- 多中心、前瞻性维护数据库(2004—2022年)回顾分析,纳入355例非肌层浸润性膀胱癌患者(295例男性、60例女性),均行机器人辅助根治性膀胱切除术加体内尿流改道。
- 采用单变量和多变量模型评估分期升级(≥pT2、≥pN1),采用Kaplan-Meier曲线预测癌症特异性生存率和总生存率。
主要发现
- 355例中,12.68%为pT2、8.2%为pT3、4.2%为pT4、5.4%为pN1、2.8%为pN2。
- 年龄≥83岁(OR 19.7)、合并原位癌与Ta/T1膀胱癌(OR 2.7)、鳞状细胞癌(OR 6.6)、变异组织学(OR 6.2)预测分期升级;体重指数≥28 kg/m2(OR 0.4)和单纯Tis(OR 0.1)降低分期升级。
- 整个队列总生存率1年为93%、5年为87%、12年为49%;癌症特异性生存率1年为97%、5年为83%、12年为76%。
- 12年时,未分期升级队列总生存率52%(95%CI 37%-74%)vs 分期升级队列39%(95%CI 26%-57%)。
- 未分期升级队列癌症特异性生存率79%(95%CI 71%-88%)vs 分期升级队列68%(95%CI 56%-82%),P < 0.001。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the 12-year survival outcomes of patients with non-muscle-invasive bladder cancer (NMIBC) who underwent robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD), focusing on those upstaged to ≥pT2 or with node-positive disease. MATERIALS AND METHODS: A multicentre, prospectively maintained database (2004-2022) was reviewed to identify patients who had undergone RARC. Univariable and multivariable models were used to assess upstaging (≥pT2, ≥pN1), and Kaplan-Meier curves were used to predict cancer-specific survival (CSS) and overall survival (OS). RESULTS: Among 355 patients with NMIBC (295 men, 60 women), 12.68% had pT2, 8.2% had pT3, 4.2% had pT4, 5.4% had pN1, and 2.8% had pN2 disease. Age ≥ 83 years (odds ratio [OR] 19.7), presence of carcinoma in situ (CIS), in combination with Ta/ T1 bladder cancer (OR 2.7), squamous cell carcinoma (OR 6.6), and variant histology (OR 6.2), predicted upstaging. A body mass index ≥28 kg/m2 (OR 0.4) and Tis alone (OR 0.1) reduced upstaging. The OS rate for the entire cohort was 93% at 1 year, 87% at 5 years and 49% at 12 years. The CSS rate was 97% at 1 year, 83% at 5 years and 76% at 12 years. At 12 years, OS was better in the non-upstaged cohort (52%, 95% confidence interval [CI] 37%-74%) vs the upstaged cohort (39%, 95% CI 26%-57%). CSS was higher in the non-upstaged cohort (79%, 95% CI 71%-88%; P < 0.001) vs the upstaged cohort (68%, 95% CI 56%-82%; P < 0.001). CONCLUSION: This study provides the longest follow-up data on RARC in NMIBC. The presence of CIS, variant histology, and pT1 on transurethral resection of the bladder tumour were predictors of upstaging, which correlated with higher recurrence and worse survival. RARC with ICUD is a minimally invasive option for NMIBC patients who need to undergo early cystectomy, offering comparable long-term outcomes.
引用
- Tillu N, Ben-David R, Skokic V, et al. Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer. BJU Int. 2025. PMID: 39980082. doi:10.1111/bju.16686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。